Compare Innodata Inc (INOD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs TransMedics Group Inc — how do they compare? Innodata Inc trades at $61.63 (market cap $2.10B), while TransMedics Group Inc trades at $77.83 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Innodata Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and TransMedics Group Inc for 24 Days on average.
| INOD | TMDX | |
|---|---|---|
Market Cap | $2.10B | $2.74B |
Volume | 989,493 | 949,331 |
Sector | Technology | Health |
52-Week High | $121.50 | $150.42 |
52-Week Low | $34.45 | $61.99 |
Typical Hold Time | 19 Days | 24 Days |
Enterprise Value | $1.86B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Innodata (INOD) trades at $60.80, down 4.12% today amid bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and robust profitability (37.74% ROE, 14.66% net margin). Recent quarterly results exceeded expectations, with Q1 2026 EPS of $0.42 beating estimates by 223%. The company is expanding into motion-capture AI and agentic reinforcement learning, positioning for growth in the AI infrastructure sector.
Despite premium valuations (P/E 47.43), INOD's strong execution and AI market positioning offer upside potential. Key risks include customer concentration and competitive pressures. Analyst consensus is bullish (66.7% buy ratings), though technical indicators suggest near-term caution with the stock trading below key resistance levels.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
